Artificial antigen-presenting cells: artificial solutions for real diseases

Area of Science:

• Immunology
• Cell Therapy
• Biotechnology

Background:

• Adoptive immunotherapy using ex vivo-generated antigen-specific T cells shows promise for treating severe diseases.
• Current methods for producing these T cells are often not reproducible or economically viable.
• Limitations exist with peptide-loaded dendritic cells in existing adoptive immunotherapy protocols.

Purpose of the Study:

• To review novel strategies for the ex vivo generation of antigen-specific T cells.
• To discuss the clinical applications of these advanced T cell generation methods.
• To highlight the potential of new approaches in adoptive immunotherapy.

Main Methods:

• Review of emerging cell-based artificial antigen-presenting cells (aAPCs).
• Review of emerging non-cell-based aAPCs.
• Analysis of strategies for ex vivo T cell expansion and engineering.

Main Results:

• Development of cell- and non-cell-based aAPCs addresses limitations of current methods.
• New strategies aim to improve the reproducibility and economic viability of T cell generation.
• These advancements facilitate the production of sufficient numbers of antigen-specific T cells.

Conclusions:

• Novel aAPC technologies are poised to overcome current hurdles in adoptive immunotherapy.
• These innovative approaches may usher in a new era of effective treatments for cancer and infectious diseases.
• The ex vivo generation of T cells is crucial for advancing cell-based therapeutic strategies.